PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 254 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $306,401 | -24.3% | 9,987 | -1.1% | 0.00% | 0.0% |
| Q2 2023 | $404,787 | +2.0% | 10,102 | +3.9% | 0.00% | 0.0% |
| Q1 2023 | $396,918 | -5.8% | 9,726 | -10.9% | 0.00% | 0.0% |
| Q4 2022 | $421,390 | -21.1% | 10,914 | +8.6% | 0.00% | -50.0% |
| Q3 2022 | $534,000 | -7.3% | 10,054 | +1.7% | 0.00% | 0.0% |
| Q2 2022 | $576,000 | -47.8% | 9,890 | -31.7% | 0.00% | 0.0% |
| Q1 2022 | $1,104,000 | +6.1% | 14,475 | -16.4% | 0.00% | 0.0% |
| Q4 2021 | $1,041,000 | +14.5% | 17,316 | +6.6% | 0.00% | -33.3% |
| Q3 2021 | $909,000 | -26.7% | 16,237 | -20.5% | 0.00% | -25.0% |
| Q2 2021 | $1,240,000 | -5.5% | 20,431 | +9.1% | 0.00% | 0.0% |
| Q1 2021 | $1,312,000 | +29.0% | 18,721 | +10.2% | 0.00% | 0.0% |
| Q4 2020 | $1,017,000 | +32.1% | 16,987 | +32.7% | 0.00% | 0.0% |
| Q3 2020 | $770,000 | +12.4% | 12,802 | -1.9% | 0.00% | 0.0% |
| Q2 2020 | $685,000 | +131.4% | 13,056 | +48.0% | 0.00% | +100.0% |
| Q1 2020 | $296,000 | -58.4% | 8,819 | -43.9% | 0.00% | -33.3% |
| Q4 2019 | $712,000 | +10.4% | 15,727 | -7.2% | 0.00% | -25.0% |
| Q3 2019 | $645,000 | -8.9% | 16,940 | +4.1% | 0.00% | 0.0% |
| Q2 2019 | $708,000 | +1.4% | 16,276 | -11.3% | 0.00% | 0.0% |
| Q1 2019 | $698,000 | -10.4% | 18,344 | +1.3% | 0.00% | -20.0% |
| Q4 2018 | $779,000 | -26.6% | 18,117 | -16.1% | 0.01% | -28.6% |
| Q3 2018 | $1,061,000 | +41.8% | 21,584 | -7.5% | 0.01% | +40.0% |
| Q2 2018 | $748,000 | -3.7% | 23,344 | -6.4% | 0.01% | 0.0% |
| Q1 2018 | $777,000 | -40.9% | 24,948 | -13.3% | 0.01% | -44.4% |
| Q4 2017 | $1,314,000 | +32.6% | 28,785 | +9.1% | 0.01% | 0.0% |
| Q3 2017 | $991,000 | -16.5% | 26,387 | +6.0% | 0.01% | -25.0% |
| Q2 2017 | $1,187,000 | +4.3% | 24,892 | -0.3% | 0.01% | 0.0% |
| Q1 2017 | $1,138,000 | +13.3% | 24,955 | -19.8% | 0.01% | +9.1% |
| Q4 2016 | $1,004,000 | +4.1% | 31,099 | +10.4% | 0.01% | -15.4% |
| Q3 2016 | $964,000 | -14.3% | 28,162 | -15.6% | 0.01% | -7.1% |
| Q2 2016 | $1,125,000 | -35.0% | 33,357 | +2.0% | 0.01% | -41.7% |
| Q1 2016 | $1,732,000 | -37.8% | 32,694 | -9.8% | 0.02% | -29.4% |
| Q4 2015 | $2,783,000 | +106.6% | 36,239 | +10.6% | 0.03% | +78.9% |
| Q3 2015 | $1,347,000 | -46.7% | 32,762 | -8.2% | 0.02% | -45.7% |
| Q2 2015 | $2,525,000 | -25.1% | 35,704 | -6.0% | 0.04% | -12.5% |
| Q1 2015 | $3,373,000 | +14.0% | 37,966 | +13.7% | 0.04% | +17.6% |
| Q4 2014 | $2,960,000 | -9.7% | 33,383 | -1.3% | 0.03% | -20.9% |
| Q3 2014 | $3,277,000 | -8.6% | 33,807 | -13.4% | 0.04% | -6.5% |
| Q2 2014 | $3,584,000 | -4.7% | 39,021 | -27.4% | 0.05% | -2.1% |
| Q1 2014 | $3,760,000 | +290.0% | 53,719 | +220.3% | 0.05% | +235.7% |
| Q4 2013 | $964,000 | -31.1% | 16,769 | -42.4% | 0.01% | -57.6% |
| Q3 2013 | $1,400,000 | +163.7% | 29,111 | +59.0% | 0.03% | +230.0% |
| Q2 2013 | $531,000 | – | 18,309 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |